Avances en el desarrollo de la terapia celular para las distrofias musculares
Year: 2016
Type: article
Abstract: Muscular dystrophies are genetic diseases characterized by progressive muscular wasting. So far, no therapy is available to cure or ameliorate the course of these pathologies; however, different experimental strategies are currently in development to tackle them. One promising approach involves the transfer of healthy cells to the patient, in order to regenerate muscle tissue. In recent years, different populations of tissue-specific stem cells have been used in cell therapy to fight muscular dystrophies. Recently, the use of embryonic stem cells and induced stem cells has provided promising results in dystrophic murine models. In this review, we recapitulated a series of studies and experimental strategies designed toward the development of an efficient cell therapy against muscular dystrophies. Abreviaturas: DMD = distrofia muscular de Duchenne. DM1 = distrofia miotonica 1. DMB = distrofia muscular de Becker. EDMD = distrofia muscular de Emery-Dreifuss. FHSD = distrofia muscular facioescapulohumeral. LGMD = distrofia muscular de la cintura y extremidades. OPMD = distrofia oculofaringea. MDSC = celulas madre derivadas de musculo. ESC = celulas madre embrionarias. EB = cuerpos embrionarios. iPSC = celulas madre pluripotenciales inducidas. TALEN = nucleasas efectoras parecidas a activadores de la transcripcion. CRISPR-Cas = repetidos palindromicos cortos regularmente espaciados y agrupados. www.medigraphic.org.mx
Source: Investigación en Discapacidad
Language: Spanish
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W2343506475